Cardiotrophin-1- Digna Biotech/Biotecnol

Drug Profile

Cardiotrophin-1- Digna Biotech/Biotecnol

Alternative Names: CT-1; Recombinant cardiotrophin-1; Recombinant CT-1

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Biotecnol SA; Digna Biotech; Genentech
  • Developer Biotecnol SA; Digna Biotech
  • Class Cytokines; Interleukins; Recombinant proteins
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ischaemia; Reperfusion injury
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetes mellitus; Liver failure

Highest Development Phases

  • Phase II Reperfusion injury
  • Phase I Acute kidney injury
  • No development reported Diabetes mellitus; Ischaemia; Liver failure; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in Spain (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-failure in Spain (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ischaemia(Prevention) in Spain (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top